HIVNET BIBLIOGRAPHY
Published Journal Articles/Book Chapters Stone E, Heagerty P, Vittinghoff E, Douglas JM, Koblin BA, Mayer KH, Celum CL, Gross M, Woody GE, Marmor M, Seage GR and Buchbinder SP. Predictors of condom failure in a sexually active cohort of men who have sex with men. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 20:495-501. 1999. Woody GE, Donnell D, Seage GR, Metzger DS, Marmor M, Koblin BA, Buchbinder SP, Gross M, Stone E and Judson FN. Non-injecting substance use correlates with risky sex among men who have sex with men: Data from HIVNET. Drug and Alcohol Dependence 53:197-205. 1999. In Press Gross M, Holte S, Seage GR, Metzger DS and Buchbinder SP. Willingness of high risk HIV-seronegative U.S. populations to join clinical trials of oral chemoprophylaxis to prevent HIV infection. [In Press] AIDS Education Prevention 1999. Bartholow BN, MacQueen KM, Douglas JM, Buchbinder SP, McKirnan DJ and Judson FN. Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr 16:108-15. 1997. Des Jarlais DC, Vanichsensi S and Marmor M. "Why I am not infected with HIV": Implications for long-term risk reduction and HIV vaccine trials. J of Acquir Immune Defic Syndr 16:393-9. 1997. Koblin BA, Avrett S, Taylor PE and Stevens CE. Willingness to participate in HIV-1 vaccine efficacy trials and the effect of media events among gay and bisexual men in New York City: Project ACHIEVE. J Acquir Immune Defic Syndr 15:165-71. 1997. Rida WN, Fast P, Hoff R and Fleming TR. Intermediate Size Trials for the Evaluation of HIV Vaccine Candidates: A Workshop Summary. J Acquir Immune Defic Syndr :195-203 1997. Seage GR, Mayer KH, Wold C, Gross M, Goldstein R, Cai B, Heeren T, Hingson R and Holmberg S. HIV and hepatitis B infection and risk behavior in young gay and bisexual men. Public Health Reports 112:158-67. 1997. Buchbinder SP, Douglas JM, McKirnan DJ, Judson FN, Katz MH and MacQueen KM. Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the U.S.: Risk behavior, seroincidence and willingness to participate. J Infect Dis 174:954-61. 1996. Des Jarlais DC, Marmor M, Paone D, Titus S, Shi Q, Perlis T, Jose B and Friedman SR. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet 348:987-91. 1996. Gross M, Seage GR, Mayer KH, Goldstein R, Losina L and Wold C. Interest among gay/bisexual men in greater Boston in participating in clinical trials of preventive HIV vaccines. J Acquir Immune Defic Syndr 12:406-12. 1996. Hennessy M, MacQueen KM, McKirnan DJ, Buchbinder SP, Judson FN, Douglas JM, Bartholow BN and Sheon AR. A factorial survey study to assess the acceptability of HIV vaccine trial designs. Controlled Clinical Trials 17:209-20. 1996. Hoff R and Lawrence DN. ; Giraldo G, Bolognesi D, Salvatore M, Beth-Giraldo E, editors.Development and applications of vaccines and gene therapy in AIDS. Switzerland: Basel, Karger, 1996;Preparation for HIV vaccine efficacy trials. p. 155-60. Koblin BA, Taylor PE, Avrett S and Stevens CE. The feasibility of HIV-1 vaccine efficacy trials among gay/bisexual men in New York City: Project ACHIEVE. AIDS 10:1555-61. 1996. Levine OS, Vlahov D, Brookmeyer R, Cohn S and Nelson KE. Differences in the incidence of hepatitis B and human immunodeficiency virus and infections among injecting drug users. J Infect Dis :579-83. 1996. MacQueen KM, Buchbinder SP, Douglas JM, Judson FN, McKirnan DJ and Bartholow BN. Required HIV antibody testing, social risk, and HIV-vaccine efficacy trials. AIDS & Public Policy Journal :104-12. 1996. Manoff SB, Vlahov
D, Herskowitz A, Solomon L, Munoz A, Cohn S, Willoughby SB and Nelson
KE. HIV infection and infective endocarditis among injecting drug
users. Epidemiology 7:566-70. 1996. Marmor M, Winchester R, Zeleniuch-Jacquotte A, Weiss SH and Krasinski K. Evidence for an effect of human leukocyte antigens on susceptibility to Kaposi's sarcoma related to charge and peptide-binding properties of class I molecules. AIDS 9:1194-5. 1996. McKirnan DJ, Ostrow DO and Hope B. Sex, drugs, escape: A psychological model of HIV risk behaviors. AIDS Care 8:655-69. 1996. Shore RE, Marmor M, Titus S and Des Jarlais DC. Methadone maintenance and other factors associated with intraindividual temporal trends in injection-drug use. Journal Substance Abuse Treatment 13:241-8. 1996. Caiaffa WT, Neil MH, Graham NM, Galai N, Rizzo RT, Nelson KE and Vlahov D. Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection. Arch Intern Med 155:2111-7. 1995 October 23. Davis RF, Metzger DS, Meyers K, McLellan AT, Mulvaney FD, Navaline HA and Woody GE. Long-term changes in psychological symptomatology associated with HIV serostatus among male injecting drug users. AIDS 9:73-9. 1995. Harrison K, Vlahov D, Jones K, Charron K and Clements M. Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. J Acquir Immune Defic Syndr 10:386-90. 1995. Levine OS, Vlahov D, Koehler J, Cohn S, Spronk AM and Nelson KE. Seroepidemiology of Hepatitis B virus in a population of injecting drug users. Am J Epidemiol 142:331-41. 1995. Meyers K, Metzger DS, McLellan AT, Navaline HA, Sheon AR and Woody GE. Will preventive HIV vaccine efficacy trials be possible with female injection drug users? J Acquir Immune Defic Syndr 10:577-85. 1995. Michaels J, Galanter M, Resnick R, Marmor M, Lifshutz H and Perrone R. Community based heroin addicts who turn to experimental treatment rather than conventional care. Journal of Addictive Diseases 14:33-42. 1995. Nelson KE, Vlahov D, Solomon L, Cohn S and Munoz A. Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, MD. Arch Intern Med 155:1305-11. 1995 June 26. Pero RW, Olsson A, Sheng Y, Hua J, Moller C, Kjellen E, Killander D and Marmor M. Progress in identifying clinical relevance of inhibition, stimulation and measurements of poly ADP-ribosylation. Biochime 77:385-93. 1995. Service SK and
Blower SM. HIV transmission in sexual networks: An empirical analysis.
Proc R Soc London 260:237-44. 1995. Wolfe H, Marmor M, Maslansky R, Nichols S, Simberkoff M, Des Jarlais DC and Moss A. Tuberculosis knowledge among New York City injecting drug users. Am J Public Health 85:985-8. 1995. Cohen E, Navaline HA and Metzger DS. High-risk behaviors for HIV: A comparison between crack-abusing and opioid-abusing African-American women. Journal of Psychoactive Drugs 26:233-41. 1994. Des Jarlais DC, Friedman SR, Sotheran JL, Wenston J, Marmor M, Yancovitz SR, Frank B, Beatrice S and Mildvan D. Continuity and change within an HIV epidemic: Injecting drug users in New York City, 1984 through 1992. JAMA 271:121-7. 1994. Douglas JM, Judson FN, Parks JP, Buchbinder SP and McKirnan DJ. Participation of homosexual/bisexual men in preventive HIV vaccine trials: Baseline attitudes and concerns and predicted behaviors during trials. AIDS Res Hum Retroviruses 10:S257-60. 1994. Dubin N, Berman S, Marmor M, Tindall B, Des Jarlais DC and Kim MY. Estimation of time since infection using longitudinal disease-marker data. Statistics in Medicine 13:231-44. 1994. Lawrence DN. HIV vaccine development to meet U.S. and international needs: Overview of a panel discussion. AIDS Res Hum Retroviruses 10:S315-6. 1994. Lawrence DN, Glass MJ and Schultz AM. Conference on advances in AIDS vaccine development-1993: Epilogue. AIDS Res Hum Retroviruses 10:S325 1994. Levine OS, Vlahov D and Nelson KE. Epidemiology of hepatitis B virus infections among injecting drug users: Seroprevalence, risk factors, and viral interactions. Epidemiologic Reviews 16:418-36. 1994. MacQueen KM, Buchbinder SP, Douglas JM, Judson FN, McKirnan DJ and Bartholow BN. The decision to enroll in HIV vaccine efficacy trials: Concerns elicited from gay men at increased risk for HIV infection. AIDS Res Hum Retroviruses 10:S261-4. 1994. Marmor M, Titus S, Wolfe H, Krasinski K, Maslansky R, Simberkoff M, Beatrice S, Nichols S and Des Jarlais DC. Preparation for AIDS vaccine trials: Retention, behavior change, and HIV-seroconversion among injecting drug users (IDUs) and sexual partners of IDUs. AIDS Res Hum Retroviruses 10:S207-13. 1994. McKirnan DJ, Doetsch J, Vanable P, Buchbinder SP, Douglas JM and Judson FN. Preparation for AIDS vaccine trials: Developing brief valid screening instruments for HIV-related sexual risk behavior among gay and bisexual men. AIDS Res Hum Retroviruses 10:S285-8. 1994. Meyers K, Metzger DS, Navaline HA, Woody GE and McLellan AT. HIV vaccine trials: Will intravenous drug users enroll? Am J Public Health 84:761-6. 1994. Navaline HA,
Snider EC, Petro CJ, Tobin D, Metzger DS, Alterman AI and Woody
GE. Preparations for AIDS vaccine trials: An automated version of
the risk assessment battery (RAB): Enhancing the assessment of risk
behaviors. AIDS Res Hum Retroviruses 10:S281-3. 1994. Sheon AR. Efficacy trials preparations colloquium II progress in domestic cohort development and evaluation. Overview: HIV vaccine feasibility studies. AIDS Res Hum Retroviruses 10:S195-6. 1994. Silberstein C, Galanter M, Marmor M, Lifshutz H, Krasinski K and Franco H. HIV-1 among inner city dually diagnosed inpatients. Am J Drug Alcohol Abuse 20:101-13. 1994. Titus S, Marmor M, Des Jarlais DC, Kim MY, Wolfe H and Beatrice S. Bleach use and HIV seroconversion among New York City injection drug users. J Acquir Immune Defic Syndr 7:700-4. 1994. Turner CF and Sheon AR. Behavioral studies relevant to vaccine trial preparation: An introduction. AIDS Res Hum Retroviruses 10:S273-6. 1994. van Griensven GJ, Koblin BA and Osmond DH. Risk behavior and HIV infection among younger homosexual men. AIDS 8:S125-30. 1994. Vlahov D. HIV vaccines for injection drug users in the context of a comprehensive prevention agenda. AIDS Res Hum Retroviruses 10:S3-6. 1994. Vlahov D, Astemborski J, Solomon L, Galai N, Basarab L and Nelson KE. Interest in HIV vaccines among injection drug users in Baltimore, Maryland. AIDS Res Hum Retroviruses 10:S265-8. 1994. Woody GE, Metzger DS and Mulvaney FD. Preparations for AIDS vaccine trials: Recruitment and retention of in- and out-of-treatment injection drug users. AIDS Res Hum Retroviruses 10:S197-9. 1994. Vermund SH, Fischer RD, Hoff R, Rida WN, Sheon AR, Lawrence DN, Hoth DF and Barker LF. Preparing for HIV vaccine efficacy trials: Partnerships and challenges. AIDS Res Hum Retroviruses 9:S127-32. 1993. Submitted Coletti AS, Heagerty P, Seage GR, Gross M, Metzger DS, Koblin BA and Sheon AR. Randomized, controlled evaluation of a prototype informed consent process for domestic HIV vaccine trials. Submitted 1998. Des Jarlais DC, Marmor M, Friedmann P, Titus S, Aviles E, Torian L, Glebatis D, Murrill C, Monterroso E and Friedman SR. HIV incidence among injecting drug users in New York City, 1992 to 1997: Evidence for a declining epidemic. Submitted 1998. Gross M, Buchbinder
SP, Holte S, Celum CL, Koblin BA and Douglas JM. Use of Reality(R)
"Female condoms" for anal sex by U.S. gay/bisexual men
at increased risk of HIV infection. Submitted 1998. Rich JD, Zhang M, Flanigan TP, King TC and Mayer KH. Letter to the Editor - Re: Case report of acute co-infection with HIV and EBV. Submitted 1998. Seage GR, Holte S, Metzger DS, Koblin BA, Gross M, Celum CL, Marmor M, Woody GE, Mayer KH, Stevens CE, Judson FN, McKirnan DJ, Sheon AR, Self S and Buchbinder SP. The HIVNET Vaccine Preparedness Study (VPS): Are United States Populations Appropriate for HIV Vaccine Trials? Submitted 1998. Spielberg F, Critchlow C, Vittinghoff E, Gross M, Coletti AS, Holt R, Mayer KH, Metzger DS, Judson FN, Marmor M, Buchbinder SP, Celum CL and Koepsell T. Acceptability of home specimen collection and telephone counseling for early detection of HIV infection: Reported attitudes. Submitted 1998 submitted. Tabet SR, Surawicz C, Horton S, Paradise MA, Coletti AS, Gross M, Fleming TR, Buchbinder SP, Haggitt RC, Levine H and Celum CL. Safety and toxicity of Nonoxynol-9 gel for possible use as a rectal microbicide. Submitted 1998. Albellanas L, Meyers K, Metzger DS and McLellan AT. AnonymousNIDA Research Monograph Series, Problems of Drug Dependence, 1993: Proceedings of the 55th Annual Scientific Meeting. 141th ed. Rockville, MD: National Institute on Drug Abuse, 1994;Latino IDUs: Do their risk behaviors differ from those IDUs of other racial groups. p. 216 Boney T, Abrams M, Meyers K, Mulvaney FD, Incmikoski R, Metzger DS, Williams J, Dyanick ST, Green P, Davis B, Johnson A and Woody GE. ; Harris LS, editors.NIDA Research Monograph Series, Problems of Drug Dependence 1994: Proceedings of the 56th Annual Scientific Meeting. 153th ed. Rockville, MD: National Institute on Drug Abuse, 1995;Retention of intravenous drug users for longitudinal assessment in HIV research and vaccine trials. p. 82 Davis RF, Metzger DS, Meyers K, Mulvaney FD, Navaline HA and Woody GE. AnonymousNIDA Research Monograph Series, Problems of Drug Dependence, 1993: Proceedings of the 55th Annual Scientific Meeting. 141th ed. Rockville, MD: National Institute on Drug Abuse, 1994;Changes in psychological symptomatology as a function of serostatus and gender among IDUs. p. 218 Frey FW, Abrutyn E, Metzger DS, Woody GE, O'Brien CP and Trusiani P. AnonymousNIDA Research Monograph Series: Social Networks, Drug Abuse, and HIV Transmission. 151th ed. Rockville, MD: National Institute on Drug Abuse, 1995;Focal networks and HIV risk among African-American intravenous drug users. p. 89-107. Fureman I, Meyers K, Metzger DS, Woody GE, McLellan AT, Navaline HA, Boney T and Kanter R. ; Harris LS, editors.NIDA Research Monograph Series, Problems of Drug Dependence 1994: Proceedings of the 56th Annual Scientific Meeting. 153th ed. Rockville, MD: National Institute on Drug Abuse, 1995;The effect of knowledge on willingness to participate in HIV vaccine trials. p. 81 Marmor M, Wolfe H, Des Jarlais DC and Moss A. ; Harris LS, editors.NIDA Research Monograph Series, Problems of Drug Dependence 1994: Proceedings of the 56th Annual Scientific Meeting. 153th ed. Rockville, MD: National Institute on Drug Abuse, 1995;Tuberculosis knowledge among New York City (NYC) injecting drug users (IDUs) and sexual partners of IDUs. p. 438 Mulvaney FD, Metzger DS, Meyers K, Davis RF, Navaline HA and Woody GE. AnonymousNIDA Research Monograph Series, Problems of Drug Dependence, 1993: Proceedings of the 55th Annual Scientific Meeting. 141th ed. Rockville, MD: National Institute on Drug Abuse, 1994;Treatment patterns among HIV positive IDU's: A longitudinal study. p. 224 Navaline HA, Metzger DS, Meyers K, Boney T, Johnson-Wilson A, Williams J, Dyanick ST, Mulvaney FD, Davis B, Abrams M, Green P, Oglesby P, Davis RF and Woody GE. ; Harris LS, editors.NIDA Research Monograph Series, Problems of Drug Dependence 1994: Proceedings of the 56th Annual Scientific Meeting. 153th ed. Rockville, MD: National Institute of Drug Abuse, 1995;HIV seroprevalence among IDU's: socio-demographic and treatment-related differences across two in- and out-of-treatment cohorts. p. 83 Navaline HA, Metzger DS, Meyers K, Dyanick ST, Williams J, Mulvaney FD, Davis RF, Johnson A and Woody GE. AnonymousNIDA Research Monograph Series, Problems of Drug Dependence, 1993: Proceedings of the 55th Annual Scientific Meeting. 141th ed. Rockville, MD: National Institute on Drug Abuse, 1994;Risk characteristics of female IDUs. p. 59 Sarro R, Metzger DS, Woody GE, Navaline HA, Oglesby P and Waskow S. AnonymousNIDA Research Monograph Series, Problems of Drug Dependence, 1993: Proceedings of the 55th Annual Scientific Meeting. 141th ed. Rockville, MD: National Institute on Drug Abuse, 1994;Quantitative changes in CD4+ T-lymphocytes for HIV+ intravenous drug users. p. 220 Presented Lenderking WR, Holte S, and Koblin BA The influence of changes in knowledge of vaccine trial concepts on willingness to participate in HIV vaccine trials over 18 months follow-up in the Vaccine Preparedness Study of the HIVNET.Anonymous Anonymous , 1999. Second Annual Conference on Vaccine Research.Bethesda, MD.March 28-30, 1999. Affleck P, Flanigan TP, Huang E, Brown-Peterside P, Smith C, Clark C and Metzger DS. Retention of (HIV-) high-risk women enrolled in the HIVNET vaccine preparedness study. 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Brown-Peterside
P, Smith C, Affleck P, Doherty-Iddings P, Borden R, Clark C and
Harrison C. Enabling women to participate in HIV vaccine efficacy
trials: Lessons learned from a US vaccine preparedness study. 12th
World AIDS Conference, Geneva, June 28-July 3, 1998. Buchbinder SP, Heagerty P, Mayer KH, Douglas JM, Celum CL, Seage GR and Koblin BA. Risk factors for HIV seroconversion in a contemporary cohort of high risk men who have sex with men (MSM). 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Celum CL, Buchbinder SP, Mayer KH, Holte S, Dondero D, Donnell D, Marmor M, Douglas JM and Sheppard HW. Characteristics of incidence seroconverters and their predominant viral type: Findings from a population-based cohort. 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Celum CL, Mayer KH, Holte S, Dondero D, Buchbinder SP, Donnell D, Douglas JM, Marmor M and Sheppard HW. Plasma and genital tract viral load and STDs in early HIV infection. 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Chesney M, Bentley ME, Morrow KM and Mayer KH. Real experience: The key to vaginal microbicide acceptability. 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Claudio J, Marmor M and Desales J. Lessons learned in opening a Phase II clinical trial of HIV vaccines to Hispanics monolinguals. Innovations and Sharing Strategies in HIV Prevention for Latinos, Philadelphia, PA, April 2-3, 1998. Coletti AS, Heagerty P, Sheon AR, Gross M, Koblin BA, Metzger DS and Seage GR. Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine efficacy trials. 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Gross M, Buchbinder SP, Holte S, Celum CL and Koblin BA. Use of Reality condoms for anal sex by HIV-seronegative US gay/bisexual men at increased risk of HIV infection. 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Gross M, Holte S, Buchbinder SP, Mayer KH, Metzger DS and Seage GR. Oral chemoprophylaxis to prevent HIV infection: Attitudes and interest among high risk HIV-negative US populations. 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Koblin BA, Holt R, Smith C, Brown-Peterside P, Holte S, Marmor M and Chiasson MA. Douching practices among US women at high risk of HIV infection, vaccine preparedness study of HIVNET. 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Marmor M. HIV risk behaviors among women who have sex with women (WSWs) enrolled in a high-risk US cohort. 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Mayer KH, Peipert JF, Fleming TR, Cu-Uvin S, Horton S, Moench T and Rosenberg Z. BufferGel: results of the first phase I study of a novel vaginal microbicide. 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Seage GR, Metzger DS, Holte S, Buchbinder SP, Koblin BA and Celum CL. Feasibility of conducting HIV-1 vaccine trials in the United States: Recruitment, retention and HIV-1 seroincidence from the HIV network for prevention trials (HIVNET) vaccine preparedness study (VPS). 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Smith C. Secondary traumatic stress syndrome: Understandings and coping mechanisms learned during HIV prevention research at the University of Illinois at Chicago. 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Spielberg F, Critchlow C, Vittinghoff E, Mayer KH, Judson FN, Coletti AS and Scotti R. Home specimen collection for early detection of HIV: Feasibility & acceptability among those at risk. 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Wilson SE, Pederson SL, Kunich JC, Wilkins VL, Mann DL, Mazzara GP, Tartaglia J, Celum CL and Sheppard HW. Cross-clade envelope Gp160, Gag p55 and Pol specific CD8+ CTL responses early following HIV-1 clade-B infection. 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Workman J. The vaccine facter in the HIV prevention community planning. 1998 HIV Prevention Summit, Washington DC, Workman J and Kanter R. Videotape in a vaccine education initiative. 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Wright J. Asking for community assistance to prepare for large HIV vaccine trials in San Francisco. 12th World AIDS Conference, Geneva, June 28-July 3, 1998. Celum CL, Donnell D, Buchbinder SP, Mayer KH, Douglas JM, Koblin BA, Flores J, Marmor M and Sheppard HW. HIV seroconverters in HIVNET (HIV Network for Prevention Trials): Natural history and STDs in early HIV infection. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-27, 1997. Celum CL, Sheppard HW, Donnell D, Wilson SE, Douglas JM, Mayer KH, Flores J, Marmor M and Buchbinder SP. HIV seroconverters in domestic HIVNET studies: Clinical, epidemiologic, virologic and immunologic findings in primary HIV infection. 9th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Bethesda, MD, May, 1997. Celum CL, Tabet SR, Dondero D, Paradise MA, Horton S, Fleming TR, Buchbinder SP and Sheppard HW. HIV viral load in rectal mucosa and plasma: Implications for pathogenesis studies and transmission. Infectious Diseases Society of America 35th Annual Meeting, 1997. Celum CL, Tabet SR, Paradise MA, Surawicz C, Chesney M, Gross M, Coletti AS, Brar H, Elliott T, Fleming TR, Sheppard HW, Rosenberg Z, Levine H, Holt R and Buchbinder SP. Safety, acceptability and biologic effects of nonoxynol-9 as a rectal microbicide. 12th International Congress of Sexually Transmitted Diseases, Seville, Spain, October 19-22, 1997. Krone MR, Tabet SR, Paradise MA, Wald A, Corey L and Celum CL. Herpes simplex virus shedding among HIV-negative, HSV-2 seropositive men who have sex with men (MSM). 12th International Congress of Sexually Transmitted Diseases, Seville, Spain, October 19-22, 1997. La Salvia TA. Challenges to recruitment and retention of women in biomedical HIV prevention research. National Conference on HIV in Women, Pasadena, CA, May 4-7, 1997. La Salvia TA and Curry P. Ten session group for HIV negative gay men. 19th National Lesbian & Gay Health Conference, Atlanta, GA, July 26-30, 1997. Mayer KH. Phase I study of a new vaginal microbicide, BufferGel: Rationale and clinical data. National Conference on HIV in Women, Pasadena, CA, May 4-7, 1997. Mayer KH, Rosenberg Z and Cates C. The current status of topical microbicides to prevent the spread of HIV and other sexually transmitted diseases. 4th International Congress on AIDS in Asia and the Pacific, Philippines, October 25-29, 1997. Tabet SR, Krone MR, Paradise MA, Stamm WE and Celum CL. Prevalence and incidence of HIV and STDS in a cohort of HIV-negative men who have sex with men (MSM). 12th International Congress of Sexually Transmitted Diseases, Seville, Spain, October 19-22, 1997. Alcabes P, Marmor M, Des Jarlais DC and Harrison C. Weight loss predicts imminent HIV seroconversion in drug injectors. 8th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Bethesda, MD, February 11-15, 1996. Alcabes P, Marmor M and Harrison C. Body-weight changes in relation to HIV seroconversion among drug injectors. 124th Annual Meeting American Public Health Association, New York, NY, November 17-21, 1996. Bartholow BN, MacQueen KM, Douglas JM, Buchbinder SP, McKirnan DJ and Judson FN. The decision to participate in HIV vaccine efficacy trials: An assessment of changing willingness among homosexual men. 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996. Blanchard LW, Strauss R, Millett G, Kegeles SM, Hayes R, Metzger DS, Fureman I and Navaline HA. Project LINCS: Working together towards effective vaccine trials. 8th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Bethesda, MD, February 11-15, 1996. Buchbinder SP, Douglas JM, McKirnan DJ, Judson FN, Scheer S and MacQueen KM. The feasibility of conducting preventive HIV vaccine trials in gay men in the United States. 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996. Cates C and O'Connell W. Scientific, social, ethical and legal issues in HIV vaccine development: What they mean to the lesbian, gay, bisexual, transgender, people of color, and other minority communities. 18th National Lesbian & Gay Health Conference, Seattle, WA, July 13-17, 1996. Celum CL. HIVNET infected participant cohort: Clinical and virologic natural history of early infection. 8th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Bethesda, MD, February 11-15, 1996. Celum CL, Buchbinder SP, Donnell D, Mayer KH, Douglas JM, Holt R and Sheppard HW. Characteristics and identification of early HIV seroconverters. 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996. Fleming TR.
Intermediate sized trials for the evaluation of HIV vaccine candidates.
8th Annual Meeting of the National Cooperative Vaccine Development
Groups for AIDS, Bethesda, MD, February 11-15, 1996. Fureman I, Metzger DS, Woody GE and Kanter R. A HIVNET recruitment videotape. 8th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Bethesda, MD, February 11-15, 1996. Gross M, Buchbinder SP, Celum CL, Critchlow C, Heagerty P and Seage GR. Relevance and feasibility of clinical trials of topical virucides designed for rectal administration among U.S. gay men. 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996. Harrison C, Marmor M, Titus S, Cord-Cruz E and Des Jarlais DC. Belief clusters among HIV-seroconverting drug users: Implications for counseling. 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996. Hartigan P and VA AIDS Study Group. Feasibility of enrollment of IDU's in an HIV seroincidence trial. 8th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Bethesda, MD, February 11-15, 1996. Hayes RB and Kegeles SM. Factors related to willingness of young gay men to participate in preventive HIV vaccine trials. 8th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Bethesda, MD, February 11-15, 1996. Koblin BA, Chiasson MA, Sackoff J, Brown-Peterside P, Taylor PE and Stevens CE. Levels of risk and readiness to change among women and gay men: Implications for future intervention trials. 8th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Bethesda, MD, February 11-15, 1996. Koblin BA, Metzger DS, Sheon AR, Critchlow C and Heagerty P. Readiness to participate in preventive HIV vaccine efficacy trials in high-risk populations in the United States. 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996. Lubin B, Scheer S, Cohen M, Pulvirenti J, Weber K, Orange E, Goodwin E, Zimmerman S, Straight C, Booth C, Cohen G, Jasek J and Pearson K. Cost and effort of recruitment and retention in minority and female clinical trials and natural history studies. 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996. MacQueen KM, Kay K, Bartholow BN, Buchbinder SP, McKirnan DJ, Judson FN and Douglas JM. The relationship between perceived exposure to HIV and actual risk in a cohort of gay and bisexual men. 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996. Marmor M, Alcabes P, Ioffe D, Krasinski K, Vogler M and Des Jarlais DC. Hepatitis B markers indicate HIV risk reduction among drug injectors. 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996. Mayer KH, Koblin
BA, Marmor M, Donnell D, Chiasson MA and Flanigan TP. Contraceptive
practices among U.S. women at increased risk for HIV acquisition.
11th International Conference on AIDS, Vancouver, Canada, July 7-12,
1996. Seage GR. Domestic vaccine preparations: What we know, where we go from here. 8th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Bethesda, MD, February 11-15, 1996. Seage GR and Metzger DS. The HIV network for efficacy trials (HIVNET) vaccine preparedness study (VPS): Goals and current status. 8th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Bethesda, MD, February 11-15, 1996. Seage GR and Metzger DS. The HIV network for efficacy trials (HIVNET) vaccine preparedness study (VPS): Goals and current status. 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 29 - February 1, 1996. Sheon AR. Social, ethical, and behavioral issues in vaccine trial participation. 8th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Bethesda, MD, February 11-15, 1996. Sherer R, Cohen M, Pulvirenti J, Weber K, Barker D, Boyer K, Henry-Reid L, Lubin B, Luskin-Hawk R and Weinstein R. Recruitment and retention of women and minorities in HIV clinical research at Cook County Hospital, Chicago, 1994-5. 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996. Stevens CE. Overview of the HIV network of prevention trials (HIVNET). 8th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Bethesda, MD, February 11-15, 1996. Stone E, O'Malley P, Scheer S, Park MS and Buchbinder SP. Should non-injection drug users be targeted for HIV prevention trials. 8th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Bethesda, MD, February 11-15, 1996. Stone E, Seage GR, Vittinghoff E, Donnell D, Koblin BA, Douglas JM and Buchbinder SP. Predictors of condom failure in a cohort of sexually active gay and bisexual men. 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996. Swenson K. HIV vaccines: Community concerns & education. 18th National Lesbian & Gay Health Conference and 14th National AIDS/HIV Forum, Seattle, WA, July 13-17, 1996. Tabet SR, Krone MR, Paradise MA, Stamm WE, Corey L and Celum CL. Herpes, the most common STD in a cohort of high-risk HIV-negative men who have sex with men. 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996. Titus S, Marmor M, Harrison C and Des Jarlais DC. Design of behavioral interventions for injection drug users promoting needle exchange using cognitive-behavioral theory. 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996. Woody GE, Metzger DS, Marmor M, Gross M, McKirnan DJ, Koblin BA and Donnell D. Substance use and risky behavior among men having sex with men. 11th International Conference on AIDS, Vancouver, Canada, July 7-12, 1996. Wuellner KA. An HIV vaccine preparedness study. 18th National Lesbian & Gay Health Conference and 14th National AIDS/HIV Forum, Seattle, WA, July 13-17, 1996. Celum CL. What it means to Be a Hero for HIV Prevention. Center for AIDS Research Seminar, University of Washington, October 5, 1995. Cu-Uvin S, Warren D, Mayer KH, Peipert JF, Anderson DJ, Klein RS, Schoenbaum E, Holmberg S, Schuman P and Vlahov D. For HER Study Group: Prevalence of genital tract infection in HIV seropositive women. "HIV in Women: Setting a New Agenda", National HIV in Women's Conference, Washington, DC, February 22-24, 1995. Fureman I, Metzger DS and Woody GE. Injection drug users' correlates of willingness to participate in HIV vaccine efficacy trials. NIAID Conference on AIDS and Drug Abuse, Scottsdale, AZ, June 9-June10, 1995. Gross M, Seage GR, Mayer KH, Goldstein G, Losina L and Wold C. Interest of gay/bisexual men in greater Boston in clinical trials of preventive HIV vaccines. 123rd Annual Meeting of the American Public Health Association, San Diego, CA, October 29-November 2, 1995. Koblin BA. Existing HIV test risk reduction behavioral prevention in the context of biomedical interventions. 3rd Science Symposium: HIV Prevention Research: Current Status and Future Directions, Flagstaff, AZ, August 16-18, 1995. Marmor M. HIV vaccine and clinical trials: Ethical concerns in industrialized countries. 6th International Congress on Ethics in Medicine, New York, NY, October 23-25,1995. Marmor M. Methodology for evaluating temporal trends in IDUs. 3rd Science Symposium: HIV Prevention Research: Current Status and Future Directions, Flagstaff, AZ, August 16-18, 1995. McKirnan DJ. HIV test risk reduction protocol development for vaccine trials. 3rd Science Symposium: HIV Prevention Research: Current Status and Future Directions, Flagstaff, AZ, August 16-18, 1995. McKirnan DJ, Vanable P, MacQueen KM, Buchbinder SP and Judson FN. Community-based interventions for safer sex among gay men: What do they consist of, who attends them, and what are their effects on sexual risk over time? 3rd Science Symposium: HIV Prevention Research: Current Status and Future Directions, Flagstaff, AZ, August 16-18, 1995. Metzger DS, Woody GE, Navaline HA and Boney T. Predictors of HIV incidence among injection drug users (IDUs) in Philadelphia. NIAID Conference on AIDS and Drug Abuse, Scottsdale, AZ, June 9-June10, 1995. Navaline HA, Metzger DS, Hammond JP, Lax L and Woody GE. Random survey of participants in a needle exchange program: HIV seroprevalence and risk behaviors. NIAID Conference on AIDS and Drug Abuse, Scottsdale, AZ, June 9-June10, 1995. Seage GR. Issues in HIV vaccine development. IBC's 5th Invitational Symposium: Clinical Trials, Boston, MA, July 19-21, 1995. Sheon AR. Lessons learned from a phase II vaccine trial for planning phase III HIV vaccine efficacy trials. IBC's 5th Invitational Symposium: Clinical Trials, Boston, MA, July 19-21, 1995. Bartholow BN, Douglas JM, McKirnan DJ, Buchbinder SP, Judson FN and MacQueen KM. The changing willingness of high-risk homosexual men to participate in HIV vaccine trials: Patterns and predictors. 7th Annual Meeting of the National Cooperative Vaccine Development Group for AIDS, Reston, VA, November 6-10, 1994. Buchbinder SP, Judson FN, McKirnan DJ, Scheer S, Park MS, Bartholow BN, Douglas JM, O'Malley P, Penley K, Doetsch J and MacQueen KM. HIV seroincidence and risk factors for HIV seroconversion in gay/bisexual men. 7th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Reston, VA, November 6-10, 1994. Buchbinder SP, Scheer S, Judson FN, Douglas JM, McKirnan DJ, O'Malley P, Sheon AR and MacQueen KM. Predictors of seroconversion in vaccine preparedness studies of gay men. 10th International Conference on AIDS, Yokohama, Japan, August 7-12, 1994. Chiasson MA, Sackoff J, Morris D, Olsen S, Koblin BA and Stevens CE. Background HIV seroincidence among minority, inner city women and their attitudes on HIV vaccine feasibility studies. 7th Annual Meeting of the National Cooperative Vaccine Development Group for AIDS, Reston, VA, November 6-10, 1994. Douglas JM, Judson FN, Parks JP, Buchbinder SP, McKirnan DJ, Bartholow BN and MacQueen KM. Persistent concerns of gay men regarding HIV vaccine trials and their relationship to feasibility study retention. 7th Annual Meeting of the National Cooperative Vaccine Development Group for Aids, Reston, VA, November 6-10, 1994. Fureman I, Metzger DS, McLellan AT and Woody GE. The impact of an HIV vaccine-related news story on a group of intravenous drug users. 7th Annual Meeting of the National Cooperative Vaccine Development Group for AIDS, Reston, VA, November 6-10, 1994. Gross M, Seage GR, Mayer KH, Goldstein R, Wold C and Losina L. Willingness of gay/bisexual men in Greater Boston to participate in clinical trials of preventive HIV vaccines. 7th Annual Meeting of the National Cooperative Vaccine Development Group for AIDS, Reston, VA, November 6-10, 1994. Judson FN, Penley K, Douglas JM, Buchbinder SP, McKirnan DJ, Bartholow BN and MacQueen KM. Experience with recruitment and retention of high-risk gay/bisexual men in HIV vaccine feasibility studies. 7th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Reston, VA, November 6-10, 1994. Koblin BA, Chambliss R, Cicatelli B, Taylor PE and Stevens CE. Project ACHIEVE: A behavioral change model for counseling gay men. 7th Annual Meeting of the National Cooperative Vaccine Development Group for AIDS, Reston, VA, November 6-10, 1994. Koblin BA, Taylor PE and Stevens CE. Has willingness to participate in HIV-1 vaccine efficacy trials changed among gay men in New York City? 7th Annual Meeting of the National Cooperative Vaccine Development Group for AIDS, Reston, VA, November 6-10, 1994. Koblin BA, Taylor PE and Stevens CE. Project ACHIEVE: A baseline study to prepare for HIV vaccine efficacy trials in New York City (NYC). 7th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Reston, VA, November 6-10, 1994. MacQueen KM. Evaluating the feasibility of conducting vaccine efficacy trials among gay men. Conference on HIV Preventive Vaccines: Social, Ethical, and Political Considerations for Domestic Efficacy Trials, Washington, DC, May 9-10, 1994. MacQueen KM, Buchbinder SP, Douglas JM, Judson FN, McKirnan DJ and Bartholow BN. HIV vaccine trials and the social significance of immunologic response. 93rd Annual Meeting American Anthropological Association, Atlanta, GA, November 30-December 4, 1994. MacQueen KM, Buchbinder SP, Douglas JM, McKirnan DJ and Bartholow BN. The decision to enroll in HIV efficacy trials: Concerns elicited from gay men at increased risk for HIV infection. Annual Meeting of the Southern Anthropological Society, Atlanta, GA, April 27-30, 1994. MacQueen KM, Buchbinder SP, Douglas JM, McKirnan DJ and Bartholow BN. Required HIV antibody testing, social harm, and HIV vaccine efficacy trials. 7th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Reston, VA, November 6-10, 1994. Marmor M, Harrison C, Cord-Cruz E, Titus S, Shore RE, Wolfe H, Simberkoff M and Des Jarlais DC. Symptoms of acute HIV infection among injecting drug users and sexual partners of injecting drug users. 7th Annual Meeting of the National Cooperative Vaccine Development Group for AIDS, Reston, VA, November 6-10, 1994. Marmor M, Titus S, Krasinski K and Pero K. Serum thiols, a surrogate measure of mononuclear leucocyte poly adenosine diphosphate ribosyl transferase activity (poly ADPRT), is related to clinical outcome of HIV infection. Conference on Impact of Biotechnology on Predictive Oncology and Therapy, International Society for Preventive Oncology, Boston, MA, December 11-13, 1994. Marmor M, Titus S, Shore RE, Wolfe H, Krasinski K, Maslansky R, Simberkoff M and Des Jarlais DC. Update on HIV vaccine preparedness studies among New York City injecting drug users (IDUs) and the sexual partners of IDUs. 7th Annual Meeting of the National Cooperative Vaccine Development Group for AIDS, Reston, VA, November 6-10, 1994. McKirnan DJ, Doetsch J, Buchbinder SP, Douglas JM and Judson FN. Stability of risk behaviors for HIV seroconversion among gay men. 7th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Reston, VA, November 6-10, 1994. McKirnan DJ, MacQueen KM, Judson FN, Douglas JM, Buchbinder SP and Vanable P. Behavioral interventions for safer sex among gay/bisexual men: What has been done, what is needed. 7th Annual Meeting of the National Cooperative Vaccine Development Group for AIDS, Reston, VA, November 6-10, 1994. Metzger DS, Woody GE, Navaline HA and Mulvaney FD. Behavioral change among injection drug users following enrollment in vaccine preparedness initiative: Implications for sample size calculations. 7th Annual Meeting of the National Cooperative Vaccine Development Group for AIDS, Reston, VA, November 6-10, 1994.
Scheer S, Buchbinder SP, O'Malley P, Park MS, Bartholow BN and MacQueen KM. Should young gay/bisexual men be targeted for enrollment in HIV vaccine trials? 7th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Reston, VA, November 6-10, 1994. Seage GR and Gross M. Domestic vaccine preparations. 7th Annual Meeting of the National Cooperative Vaccine Development Group for AIDS, Reston, VA, November 6-10, 1994. Sheon AR, Buchbinder SP, Davenny K, Judson FN, MacQueen KM, McKirnan DJ, Metzger DS, Marmor M and Nelson KE. The feasibility of vaccine efficacy trials in gay men and IDU's in the USA. 10th International Conference on AIDS, Yokohama, Japan, August 7-12, 1994. Woody GE, Metzger DS, Navaline HA and Boney T. Two year seroconversion and mortality rates among injection drug users participating in vaccine preparedness studies: Lessons for recruitment and trial procedures. 7th Annual Meeting of the National Cooperative Vaccine Development Group for AIDS, Reston, VA, November 6-10, 1994. Hoff R. The HIV vaccine efficacy trials network (HIVNET). Conference on Advances in AIDS Vaccine Development, Alexandria, VA, October, 1993. Sheon AR. Domestic HIV vaccine efficacy preparatory studies: Their key role in preparedness. 6th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Alexandria, VA, October 30-November 4, 1993. Accepted None. Submitted Colfax G, Buchbinder SP, Metch B, Holte S, Scheer S, and Stevens CE Recruitment of high-risk individuals into HIV vaccine trials: Barriers to enrollment and predictors of participation a phase II trial.Anonymous Anonymous , 1999. 1999 National HIV Prevention Conference.Atlanta, GA. HIVNET Home | Community Education | Contact Us | HIVNET Research Sites | HIVNET Science | What is HIVNET? | Resources |